Oncotelic Therapeutics, Inc. (OTLC)

OTCMKTS: OTLC · Delayed Price · USD
0.0850
-0.0050 (-5.56%)
Aug 12, 2022 4:00 PM - Market closed
-5.56%
Market Cap 32.18M
Revenue (ttm) n/a
Net Income (ttm) -11.44M
Shares Out 378.63M
EPS (ttm) -0.03
PE Ratio n/a
Forward PE 12.97
Dividend n/a
Ex-Dividend Date n/a
Volume 146,364
Open 0.0910
Previous Close 0.0900
Day's Range 0.0850 - 0.0930
52-Week Range 0.0800 - 0.2600
Beta -0.15
Analysts Buy
Price Target 4.08 (+4,700.0%)
Earnings Date n/a

About OTLC

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the t... [Read more...]

Industry Biotechnology
IPO Date Aug 26, 1993
Employees 16
Stock Exchange OTCMKTS
Ticker Symbol OTLC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for OTLC stock is "Buy." The 12-month stock price forecast is 4.08, which is an increase of 4,700.00% from the latest price.

Price Target
$4.08
(4,700.00% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Oncotelic Announces Presentation of P001- OT-101 Phase 1/2 Trial in Pancreatic Cancer

AGOURA HILLS, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including Parki...

Oncotelic Provides Update on OT-101 at the 2022 BIO International Convention

AGOURA HILLS, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including Parki...

Oncotelic Therapeutics Receives FDA Clearance for Phase 2 Clinical Trial of OT-101/Pembroluzimab Combination for Meso...

AGOURA HILLS, Calif., May 25, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), a developer of treatments for rare and orphan indications, including Park...

ONCOTELIC PROVIDES Q1 2022 FINANCIAL RESULTS COMPARED TO Q1 2021, PRODUCT DEVELOPMENT INITIATIVES AND CORPORATE UPDATE

AGOURA HILLS, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“ Oncotelic ” , “ We ” or the “ Company ”) ( OTCQB: OTLC ) today announced financial results for the three months end...

ONCOTELIC PROVIDES YE 2021 FINANCIAL RESULTS COMPARED TO YE 2020, PRODUCT DEVELOPMET INITIATIVES AND CORPORATE UPDATE

AGOURA HILLS, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“ Oncotelic ” , “ We ” or the “ Company ”) (OTCQB: OTLC ) today announced financial results for the full year ended...

Letter to Oncotelic Shareholders on the Recently Completed Joint Venture Transaction with Dragon Overseas Capital Lim...

AGOURA HILLS, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“ Oncotelic ” or the “Company”) (OTCQB :OTLC ), issued the following shareholder letter today.

Oncotelic to Present New Studies on its TGF-β Program at the American Association for Cancer Research (AACR) Annual M...

AGOURA HILLS, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“ Oncotelic ” or the “Company”) ( OTCQB:OTLC ), a leading developer of TGF-β therapeutics for oncology and virology...

Dr. Anthony E. Maida will be presenting at the Marcus Evans Evolution Summit

AGOURA HILLS, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“ Oncotelic ” or the “Company”) ( OTCQB:OTLC ), and Marcus Evans are proud to announce Dr Anthony E. Maida, Chief C...

Oncotelic Presenting at MedInvest Pharmaceutical and Biotechnology Investor Conference

AGOURA HILLS, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ( “ Oncotelic ” or the “ Company ” ) ( OTCQB:OTLC ) , a leading developer of TGF-β therapeutics for oncology and viro...

Oncotelic Presenting at BiotechGate Digital Partnering

AGOURA HILLS, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ( “ Oncotelic ” or the “ Company ” ) (OTCQB:OTLC) , a leading developer of TGF-β therapeutics for oncology and virolo...

Oncotelic Initiates Phase 1 Trial Evaluating CA4P in Combination with Pembrolizumab for Melanoma

AGOURA HILLS, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (" Oncotelic " or the "Company") ( OTCQB:OTLC ) , a leading developer of TGF-β therapeutics for oncology and virology...

ONCOTELIC ANNOUNCES THAT ORF8 MUTATIONS ARE DRIVING THE EVOLUTION OF THE DELTA AND THE OMICRON VARIANTS.

AGOURA HILLS, Calif., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") ( OTCQB:OTLC ) , a leading developer of TGF-β therapeutics for oncology and virology, ...

MATEON ANNOUNCES INITIATION OF PHASE 1B CLINICAL TRIAL ON OT-101/IL-2 COMBINATION THERAPY FOR SOLID TUMORS

AGOURA HILLS, California, March 15, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) today announced the regulatory approval from the Ministry of Food and Drug Safety of Korea for the phas...

MATEON'S UPDATE ON C001 - GLOBAL STUDY FOR OT-101 AGAINST COVID-19

PART 1 AND 2 SENTINEL PATIENTS COMPLETED TREATMENT

MATEON THERAPEUTICS AND WINDLAS BIOTECH LAUNCH INDIA'S FIRST COMBINED LUNG THERAPY AND AI TELEMEDICINE 360° SOLUTION ...

AGOURA HILLS, California, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious disease and respirato...

MATEON PARTNERED WITH CHOPRA FOUNDATION ON ARTIVEDA™

AGOURA HILLS, California, Feb. 16, 2021 (GLOBE NEWSWIRE) --  Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious disease and respirat...

MATEON ANNOUNCES COMPLETION OF ARTI-19 AND PUBLICATION OF POSITIVE INTERIM DATA

AGOURA HILLS, California, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious diseases, announced t...

MATEON LAUNCHES ITS AI TELEMEDICINE PLATFORM FOR POST MARKETING SURVEY TO SUPPORT ITS DRUG PRODUCT FOR INDIA, PULMOHEAL™

AGOURA HILLS, California, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious diseases, announce to...

MATEON LAUNCHING MOBILE APP, ARTIHEALTH™, FOR REMOTE RESPIRATORY HEALTH ASSESSMENT

AGOURA HILLS, California, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious diseases, announced t...

MATEON ANNOUNCES POSITIVE INTERIM RESULTS FROM ARTI-19 CLINICAL TRIAL EVALUATING COVID-19 THERAPEUTIC

AGOURA HILLS, California, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and COVID-19, reported positive int...

MATEON'S GLOBAL STUDY FOR OT-101/ TGF-β INHIBITOR AGAINST COVID-19 ENROLLS AND TREATS ITS FIRST PATIENT

AGOURA HILLS, Calif., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB:MATN) announced today that it has enrolled and treated its first sentinel Part 1 pati...